| 3.71 -0.28 (-7.02%) | 04-06 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Standard BioTools Inc. is a global enterprise dedicated to the development, production, and distribution of sophisticated instruments, expendable supplies, specialized chemical reagents, and software solutions for both scientific research and clinical diagnostic laboratories worldwide. The company's comprehensive product lineup features advanced analytical platforms such as the Helios CyTOF system, alongside Hyperion imaging systems, Hyperion tissue imagers, and flow conductors. To support biological investigations, they provide a range of assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits, particularly valuable in immuno-oncology research. Their offerings also encompass preparatory instrumentation like the Juno systems, as well as high-performance analytical systems such as the Biomark HD system and EP1 system. A core element of their technology involves integrated fluidic circuits (IFCs), available in multiple configurations including library preparation IFCs, Juno genotyping IFCs, dynamic array IFCs, digital array IFCs, and Flex Six IFCs. Complementing these, they offer an extensive array of assays and reagents, spanning Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers, targeted sequencing prep primers, and targeted DNA Seq library assays. Furthermore, Standard BioTools specializes in single-cell microfluidics with its C1 systems and corresponding C1 IFCs, augmented by various software solutions. Their diverse customer base includes academic research institutions, translational research and medicine centers, cancer centers, clinical research laboratories, biopharmaceutical and biotechnology companies, plant and animal research organizations, and contract research organizations. The company holds significant license agreements with esteemed institutions such as the California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. Established in 1999 under its initial name, Mycometrix Corporation, the firm rebranded to Fluidigm Corporation in April 2001 and maintains its headquarters in South San Francisco, California.
Mon, 24 Jan 2022
Hedge funds take stake in biotech equipment maker Fluidigm with plans for new name, CEO - The Business Journals
Mon, 24 Jan 2022
Fluidigm Announces $250 Million Strategic Capital Infusion - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|